Farmas USA

OCAT

Es que me habías colgado el enlace de otro lado. Ah, sí, y el partner en plaquetas saldrá en breve, aunque ya prácticamente sabemos quién es. Es un productor de plaquetas pequeñajo pero sólido y al que le va a caer una financiación gorda gubernamental en breve.

Hala, ya que estamos, pongo el resumen completo

Cell-based therapies, such as adult tissue-derived mesenchymal stromal cells (MSCs) are showing promise in small clinical trials for systemic lupus erythematosus (SLE). However, the inability to manufacture large scale quantities from a single donor without compromising functionality limits their utility while the use of multiple donors leads to variability in MSC quality. Hemangio-mesenchymal cells (HMCs), which have immunomodulatory properties similar to MSCs but are derived from a virtually inextinguishable human embryonic stem cell (hESC) source, can circumvent issues regarding scalability and consistent quality. Here, we show that HMCs have therapeutic utility in SLE; they extend the survival of lupus-prone NZB x NZW F1 (also referred to as BWF1) mice by preventing progression of their otherwise fatal lupus nephritis (LN). HMC treatment led to statistically significant reductions in proteinuria and serum creatinine. They preserved renal architecture and prevented interstitial inflammation and protein cast formation. HMC treatment led to significant reductions in the circulating levels of tumor necrosis alpha (TNFα) and interleukin 6 (IL-6), two inflammatory cytokines implicated in SLE progression. Mechanistically, in vitro data support these findings as co-culture of HMCs with lipopolysaccharaide (LPS)-stimulated BWF1 lymphocytes decreased the secretion of TNFα and IL-6 into the culture supernatant. Moreover, co-culture of HMCs enhanced the percentage of regulatory T cells in the BWF1 lymphocyte pool. Collectively, these results suggest that HMC immunomodulatory capabilities are therapeutically useful and represent an important step in the development of a commercially scalable and efficacious cell-based treatment for SLE/LN.

RXII

Vendidas todas a 0.395

NYMX - PBYI - NVAX - LLBO - GERN

Ande'vas perraaaaa!!!!
THLD

Besana
No soy bajista soy un poco bajo, vamos tipo Alfredo Landa, sólo soy el Dj al que en plena fiesta le pides un tema y te mira diciendo, yo soy el que pone la música. Pongo cosas diferentes al resto.

Ocat
Dejaros de lamberos los unos a los otros, que baboseo, buy and hold 4 años.
:)

CTIX, atacando de nuevo la cota de los 2$....
Habría que superar los 2,04 y cerrar por encima...

CTIX

GERN

Maaaadre mía Templarium, qué cagallón hemos comprado. Me voy a esperar al cierre por si baja más promediar para salirme cuanto antes. Al fin y al cabo solo subieron un +15%, peor sería que hubieran subido un +60% para salirse. Yo creo que promediando se podrá salir bien con nulas o pocas pérdidas.

El día 9, pues parece entrada por que la empresa lo merece,
buscando unos buenos resultados.

CytRx Announces the Presentation of its Phase 2b Clinical Trial Design in Small Cell Lung Cancer at the World Conference on Lung Cancer in Denver, Colorado
LOS ANGELES, Sept. 3, 2015 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the Phase 2b clinical trial design of its clinical trial in small-cell lung cancer (SCLC) will be presented in the P3.07 Poster Session on SCLC at the 16th World Conference on Lung Cancer in Denver, Colorado, September 6 - 9, 2015. Entitled "Phase 2 Study of Aldoxorubicin versus Topotecan for Relapsed/Refractory Small Cell Lung Cancer" (Poster # 1736), the poster will be available starting at 9:30 AM MDT, on September 9, 2015. Additionally, aldoxorubicin will be discussed in the Novel SCLC Therapies Mini Symposium (MS 16) on September, 8, 2015.

"We are pleased to present the aldoxorubicin Phase 2b clinical trial design in SCLC at the World Conference on Lung Cancer," said Steven A. Kriegsman, Chairman and Chief Executive Officer. "We believe this will raise awareness of aldoxorubicin's potential to treat patients with relapsed or refractory SCLC, a devastating disease with a large unmet need. In prior Phase 1 trials, we have seen encouraging evidence of SCLC patients with tumor shrinkage and prolonged stable disease. Our previous data in relapsed or refractory solid tumor patients indicates that the dose of aldoxorubicin being administered to these patients is well tolerated and without any treatment-limiting side effects. Up to 21 cycles (4.8 grams/m2) have been given to one patient with small cell lung cancer with minimal side effects and good anti-tumor activity."

The Phase 2b trial is currently enrolling 132 patients at 37 sites in the USA, Hungary and Spain. Patients with metastatic small cell lung cancer who have either relapsed or were refractory to prior chemotherapy will receive either aldoxorubicin or topotecan in a 1:1 randomization. The primary endpoint for the trial is progression-free survival. Overall survival and safety are secondary endpoints.

CYTR